In vitro activity of evernimicin and selected antibiotics against methicillin-resistant staphylococci: A 24-country study

Clinical Microbiology and Infection

Volumn 6, Issue 10, 2000, Pages 549-556

  Goering, R ^a   Nora, C E ^b   Hare, R ^c   Sabatelli, F ^c   Aldridge, K ^d   Della Latta, P ^d   Dick, J ^d   Ferraro, M J ^d   Hindler, J ^d   Bruckner, D ^d   Jacobs, M ^d   Jones, R ^d   Low, D ^d   Medeiros, A ^d   Boyce, J ^d   Murray, B ^d   Baquero, F ^d   Costa, D ^d   Frimodt Moller, N ^d   Goossens, H ^d   Graninger, D ^d   Gudmundsson, S ^d   Gur, D ^d   Huovinen, P ^d   Kettner, M ^d   Keuleyan, E ^d   Klugman, K ^d   Le Clercq, R ^d   Patzer, J ^d   Petrikkos, G ^d   Lingas, E ^d   Nord, C E ^d   Reshedko, G ^d   Stratchounski, L ^d   Schindler, J ^d   Schito, G C ^d   Verhoef, J ^d   Wiedermann, B ^d   Wise, R ^d   more..

^a CREIGHTON UNIVERSITY MEDICAL CENTER   (United States)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c MERCK RESEARCH LABORATORIES   (United States)

^d NONE

Author keywords

Evernimicin; Multiresistant staphylococci; Surveillance

Indexed keywords

ANTIBIOTIC AGENT; CIPROFLOXACIN; DALFOPRISTIN PLUS QUINUPRISTIN; ERYTHROMYCIN; EVERNIMICIN; METICILLIN; OXACILLIN; VANCOMYCIN;

ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIUM ISOLATE; CLINICAL LABORATORY; COAGULASE NEGATIVE STAPHYLOCOCCUS; CONTROLLED STUDY; DATA ANALYSIS; EUROPE; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NORTH AMERICA; PREVALENCE; PRIORITY JOURNAL; SOUTH AFRICA;

BACTERIA (MICROORGANISMS); METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS;

EID: 0034309817     PISSN: 1198743X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1469-0691.2000.00167.x     Document Type: Article

References (25)

1. Dornbusch K, King A, Legakis N. Incidence of antibiotic resistance in blood and urine isolates from hospitalized patients. Report from a European collaborative study. European Study Group on Antibiotic Resistance (ESGAR). Scand J Infect Dis 1998; 30: 281-8.
2. Johnson AP. Antibiotic resistance among clinically important gram-positive bacteria in the UK. J Hosp Infect 1998; 40: 17-26.
3. Speller DC, Johnson AP, James D, Marples RR, Charlett A, George RC. Resistance to methicillin and other antibiotics in isolates of Staphylococcus aureus from blood and cerebrospinal fluid, England and Wales, 1989-95. Lancet 1997; 350: 323-5.
4. Coronado VG, Edwards JR, Culver DH, Gaynes RP. Ciprofloxacin resistance among nosocomial Pseudomonas aeruginosa and Staphylococcus aureus in the United States. National Nosocomial Infections Surveillance (NNIS) System. Infect Control Hosp Epidemiol 1995; 16: 71-5.
5. Centers for Disease Control. Staphylococcus aureus with reduced susceptibility to vancomycin-United States, 1997. JAMA 1997; 278: 891-2.
6. Hiramatsu K, Aritaka N, Hanaki H et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 1997; 350: 1670-3.
7. Smith TL, Pearson ML, Wilcox KR et al. Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group. N Engl J Med 1999; 340: 493-501.
8. Perl TM. The threat of vancomycin resistance. Am J Med 1999; 106(5A): 26S-37S.
9. Anonymous. Update: Staphylococcus aureus with reduced susceptibility to vancomycin-United States, 1997. MMMR Weekly 1997; 46: 813-15.
10. Melo-Cristino J. Antimicrobial resistance in staphylococci and enterococci in 10 Portuguese hospitals in 1996 and 1997. POSGAR. Portuguese Study Group of Antimicrobial Resistance. Microb Drug Resist 1998; 4: 319-24.
11. de Neeling AJ, van Leeuwen WJ, Schouls LM et al. Resistance of staphylococci in The Netherlands: surveillance by an electronic network during 1989-1995. J Antimicrob Chemother 1998; 41: 93-101.
12. Kristensen B, Smedegaard HH, Pedersen HM et al. Antibiotic resistance patterns among blood culture isolates in a Danish County 1981-1995. J Med Microbiol 1999; 48: 67-71.
13. Turnidge JD, Nimmo GR, Francis G. Evolution of resistance in Staphylococcus aureus in Australian teaching hospitals. Australian Group on Antimicrobial Resistance (AGAR). Med J Aust 1996; 164: 68-71.
14. Cormican MG, Jones RN. Emerging resistance to antimicrobial agents in gram-positive bacteria. Enterococci, staphylococci, and nonpneumococcal streptococci. Drugs 1996; 51 (suppl 1): 6-12.
15. Sloos JH, van de Klundert JA, Dijkshoorn L, van Boven CP. Changing susceptibilities of coagulase-negative staphylococci to teicoplanin in a teaching hospital. J Antimicrob Chemother 1998; 42: 787-91.
16. Del'Alamo L, Cereda RF, Tosin I, Miranda EA, Sader HS. Antimicrobial susceptibility of coagulase-negative staphylococci and characterization of isolates with reduced susceptibility to glycopeptides. Diagn Microbiol Infect Dis 1999; 34: 185-91.
17. Urban C, Mariano N, Mosinka-Snipas K, Wadee C, Chahrour T, Rahal JJ. Comparative in vitro activity of SCH 27899, a novel everninomicin, and vancomycin. J Antimicrob Chemother 1996; 37: 361-4.
18. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial disk susceptibility tests, 6th edn. Approved standard M2-A6. Wayne, PA: NCCLS, 1997.
19. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing. Supplemental tables, M100-S9. Wayne, PA: NCCLS, 1999.
20. Marshall SA, Jones RN, Erwin ME. Antimicrobial activity of SCH27899 (Ziracin), a novel everninomicin derivative, tested against Streptococcus spp.: disk diffusion/etest method evaluations and quality control guidelines. The Quality Control Study Group. Diagn Microbiol Infect Dis 1999; 33: 19-25.
21. Thornsberry C, Yee YC. Comparative activity of eight antimicrobial agents against clinical bacterial isolates from the United States, measured by two methods. Am J Med 1996; 100(6A): 26S-38S.
22. Banfield CR, Glue P, Affrime MB et al. Multiple-dose safety, tolerance and pharmacokinetics of Ziracin (SCH27899): a new, novel oligosaccharide antibiotic [abstract A-114]. In: 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto. Washington, DC: American Society for Microbiology, 1997: 23.
23. Bauernfeind A, Eberlein E, Jungwirth R. Comparative bactericidal kinetics of SCH27899 (Ziracin) at various doses in a pharmacodynamic model [abstract A-33]. In: 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto. Washington, DC: American Society for Microbiology, 1997: 7.
24. Verga O, Craig WA. In vivo pharmacodynamic activity of SCH27899 (SCH, Ziracin), an everninomicin antibiotic [abstract A-32]. In: 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto. Washington, DC: American Society for Microbiology, 1997: 6.
25. Garrett DO, Jochimsen E, Murfitt K et al. The emergence of decreased susceptibility to vancomycin in Staphylococcus epidermidis. Infect Control Hosp Epidemiol 1999; 20: 167-70.